This site is intended for US healthcare professionals only.

    Get to the core

    Overall
    response rate
    (ORR)*

    25.3%

    (95% CI:
    16.4-36.0)

    For Adult Patients With
    Relapsed or Refractory Multiple Myeloma (RRMM)
    With the first and only FDA-approved oral XPO1 inhibitor1
    XPOVIO® (selinexor) + dexamethasone demonstrated clinically significant responses in adult patients with RRMM whose disease was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide, and daratumumab (N=83).
    *Includes stringent complete response (sCR) + complete response (CR) + very good partial response (VGPR) + partial response (PR). ORR as assessed by an Independent Review Committee (IRC) based on the International Myeloma Working Group (IMWG) Uniform Response Criteria for Multiple Myeloma was the primary efficacy endpoint in the STORM Part 2 clinical trial.

    Reference: 1. XPOVIO (selinexor) [package insert]. Newton, MA: Karyopharm Therapeutics Inc.; June 2020.

    INDICATIONS

    • XPOVIO® (selinexor) in combination with dexamethasone is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies and whose disease is refractory to at least 2 proteasome inhibitors, at least 2 immunomodulatory agents, and an anti-CD38 monoclonal antibody.
    • XPOVIO is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy.

    IMPORTANT SAFETY INFORMATION

    Thrombocytopenia: XPOVIO can cause life-threatening thrombocytopenia, potentially leading to hemorrhage. Thrombocytopenia was reported in patients with multiple myeloma (MM) and developed or worsened in patients with DLBCL.

    Thrombocytopenia is the leading cause of dosage modifications. Monitor platelet counts at baseline and throughout treatment. Monitor more frequently during the first 3 months of treatment. Institute platelet transfusion and/or other treatments as clinically indicated. Monitor patients for signs and symptoms of bleeding and evaluate promptly. Interrupt, reduce dose, or permanently discontinue based on severity of adverse reaction.